In a paper published in the July 31 issue of Science Translational Medicine, researchers at Fred Hutchinson Cancer Research Center used CRISPR-Cas9 to edit long-lived blood stem cells to reverse the clinical symptoms observed with several blood disorders, including sickle cell disease and beta-thalassemia.
It’s the first time that scientists have specifically edited the genetic makeup of a specialized subset of adult blood stem cells that are the source of all cells in the blood and immune system.
The proof-of-principle study suggests that efficient modification of targeted stem cells could reduce the costs of gene-editing treatments for blood disorders and other diseases while decreasing the risks of unwanted effects that can occur with a less discriminating approach.
“By demonstrating how this select group of cells can be efficiently edited for one type of disease, we hope to use the same approach for conditions such as HIV and some cancers,” said senior author Dr. Hans-Peter Kiem, director of the Stem Cell and Gene Therapy Program and a member of the Clinical Research Division at Fred Hutch.
“Targeting this portion of stem cells could potentially help millions of people with blood diseases,” said Kiem, who holds the Stephanus Family Endowed Chair for Cell and Gene Therapy.
For this preclinical study, which is expected to lead to human trials, the researchers picked a gene related to sickle cell disease and beta-thalassemia, which are caused by a genetic defect in how hemoglobin is made. Other studies have shown that symptoms are reversed by reactivating a version of hemoglobin that works during fetal development but is then turned off by our first birthdays.
The Fred Hutch researchers used CRISPR-Cas9 gene editing to a remove a piece of genetic code that normally turns off fetal hemoglobin proteins. Snipping this control DNA with CRISPR enables red blood cells to continuously produce elevated levels of fetal hemoglobin.
The edits were taken up efficiently by the targeted cells: 78% took up the edits in the lab dish before they were infused. Once infused, the edited cells settled in (“engrafted”), multiplied and produced blood cells, 30% of which contained the edits. This resulted in up to 20% of red blood cells with fetal hemoglobin, the type of hemoglobin that reverses disease symptoms in sickle cell disease and thalassemia.
“Not only were we able to edit the cells efficiently, we also showed that they engraft efficiently at high levels, and this gives us great hope that we can translate this into an effective therapy for people,” Kiem said. “Twenty percent of red blood cells with fetal hemoglobin — what we saw with this method — would be close to a level sufficient to reverse symptoms of sickle cell disease.”
The scientists also believe that carrying out genetic fixes on the smaller pool of cells required for therapeutic benefit will lessen safety concerns and reduce the risk of off-target effects.
“Since the CRISPR technology is still in early stages of development, it was important to demonstrate that our approach is safe. We found no harmful off-target mutations in edited cells and we are currently conducting long-term follow-up studies to verify the absence of any undesired effect,” said first author Dr. Olivier Humbert, a staff scientist in the Kiem Lab.
This was the first study to specifically edit a small population of blood cells that Kiem’s team identified in 2017 as solely responsible for regrowing the entire blood and immune system. His team distinguished this select group as CD90 cells, named for a protein marker that sets them apart from the rest of the blood stem cells (known by another protein marker, CD34).
The self-renewing properties of this population of stem cells make them a powerful potential candidate to deliver gene therapy because they can provide long-term production of these genetically modified blood cells and thus could cure a disease for an entire lifetime. Since they represent a mere 5% of all blood stem cells, targeting them with gene-editing machinery would require fewer supplies and potentially be less costly.
The National Heart, Blood, and Lung Institute of the National Institutes of Health supported the research under award number R01 HL136135.
Materials provided by Fred Hutchinson Cancer Research Center. Note: Content may be edited for style and length.